Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Grifols (NASDAQ:GRFS – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.
Analyst Recommendations
This is a summary of recent ratings for Fate Therapeutics and Grifols, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Fate Therapeutics | 1 | 1 | 4 | 0 | 2.50 |
| Grifols | 1 | 2 | 0 | 0 | 1.67 |
Fate Therapeutics currently has a consensus target price of $5.80, indicating a potential upside of 408.77%. Grifols has a consensus target price of $9.00, indicating a potential upside of 3.09%. Given Fate Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than Grifols.
Valuation and Earnings
This table compares Fate Therapeutics and Grifols”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Fate Therapeutics | $4.75 million | 29.18 | -$136.32 million | ($1.03) | -1.11 |
| Grifols | $8.51 billion | 0.70 | $454.82 million | N/A | N/A |
Grifols has higher revenue and earnings than Fate Therapeutics.
Institutional and Insider Ownership
97.5% of Fate Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Fate Therapeutics and Grifols’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Fate Therapeutics | -1,941.09% | -73.92% | -45.16% |
| Grifols | 5.54% | 6.21% | 2.39% |
Volatility & Risk
Fate Therapeutics has a beta of 2.65, indicating that its share price is 165% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500.
Summary
Fate Therapeutics beats Grifols on 7 of the 12 factors compared between the two stocks.
About Fate Therapeutics
Fate Therapeutics is a clinical-stage biotechnology company based in San Diego, California. It develops cellular immunotherapies using induced pluripotent stem cells (iPSCs), which can be engineered and used to produce populations of therapeutic cells. The company’s research focuses on off-the-shelf cell therapies, including natural killer (NK) cell and T-cell programs designed to target cancer. Its approach aims to create standardized therapies that do not require cells to be collected from each individual patient.
About Grifols
Grifols is a global healthcare company headquartered in Barcelona, Spain, focused on developing and producing plasma-derived medicines and other healthcare products. Founded in 1909, the company has expanded from its origins in laboratory services into a business spanning plasma collection, biopharmaceuticals, diagnostics and hospital solutions. Its biopharmaceutical business collects and processes human plasma to make medicines, including immunoglobulins, albumin and coagulation factors. Grifols also supplies diagnostic products and services for transfusion medicine and offers products used in hospitals and clinical laboratories.
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
